Skip to main content

Table 3 Lesion severity (in %) in dogs treated once with oral or topical fluralaner (Day 0) or twice with oral sarolaner (Days 0 and 28). Only the worst lesion was considered in a dog with more than one lesion

From: Efficacy of orally and topically administered fluralaner (Bravecto®) for treatment of client-owned dogs with sarcoptic mange under field conditions

 

Day 0

Day 28

Day 56

Day 84

Oral fluralaner

    

 None

0.0

48.1

85.2

98.1

 Mild

27.8

48.2

14.8

 Moderate

48.1

3.7

 Severe

24.1

1.9a

Topical fluralaner

    

 None

0.0

41.3

89.1

100.0

 Mild

13.0

52.2

8.7

 Moderate

56.5

4.3

2.2

 Severe

30.5

2.2

Oral sarolaner

    

 None

3.9

42.3

84.6

100.0

 Mild

7.7

38.5

11.5

 Moderate

57.7

19.2

3.9

 Severe

30.7

  1. aSkin lesion assessed as trunk pyoderma unrelated to sarcoptic mange